Ritter Pharmaceuticals Appoints Esteemed Gastroenterologist Anthony J. Lembo, M.D. to its Medical Advisory Board
August 13, 2019 09:15 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call
August 08, 2019 14:16 ET
|
Ritter Pharmaceuticals, Inc.
Market research indicates an unmet need for better lactose intolerance treatments and interest from both patients and physicians in the RP-G28 drug profile LOS ANGELES, Aug. 08, 2019 (GLOBE...
Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings
July 31, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
Daniel P. Lundberg, Consultant to Ritter Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals to address market opportunity for Phase 3, lactose intolerance drug candidate RP-G28...
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
July 11, 2019 17:28 ET
|
Ritter Pharmaceuticals, Inc.
Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES, July 11, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the...
Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance
July 02, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update
June 20, 2019 09:15 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 20, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals Shares New Market Research Illuminating the Life Challenges of a Lactose Intolerance Sufferer
May 30, 2019 07:00 ET
|
Ritter Pharmaceuticals, Inc.
Current treatment options only provide full symptom relief to 9% of patients; 90% of sufferers want a better solution LOS ANGELES, May 30, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc....
Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019
May 14, 2019 19:57 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 14, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
May 07, 2019 09:15 ET
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Ritter Pharmaceuticals Reports Year End 2018 Financial Results and Provides Business Update
March 29, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, March 29, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...